Hirofumi Yasue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hirofumi Yasue has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
Eisaku Harada
Division of Cardiovascular Medicine, Kumamoto Kinoh Hospital, Kumamoto Aging Research Institute
16 shared publicationsYuji Mizuno
Division of Cardiovascular Medicine, Kumamoto Kinoh Hospital, Kumamoto Aging Research Institute
16 shared publicationsMichihiro Yoshimura
Division of Cardiology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
12 shared publicationsHisao Ogawa
Department of Cardiovascular Medicine, Faculty of Life Science, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
10 shared publicationsTeruhiko Ito
7 shared publicationsYoshihiko Saito
First Department of Internal Medicine, Nara Medical University, Kashihara, Japan
7 shared publications
Latest Publications
- Open Access
- 25 September 2025
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 89 (10) , 1719-1721
Sex-Specific Association Between Calcium-Channel Blocker Use and B-Type Natriuretic Peptide Levels in Elderly Hypertensive Patients With Heart Failure With Preserved Ejection Fraction
Background: The effects of calcium-channel blockers (CCBs) in heart failure with preserved ejection fraction (HFpEF), particularly by sex, remain unclear.Methods and Results: We retrospectively analyzed 412 elderly hypertensive patients with HFpEF (308 women, 104 men). Female CCB users had significantly lower B-type natriuretic peptide (BNP) levels. Multivariable regression showed that CCB use was independently associated with lower BNP, higher EF, and lower tricuspid regurgitation pressure gradient in women, but not in men.Conclusions: CCB use, particularly amlodipine, may be associated with sex-specific hemodynamic benefits in hypertensive elderly women with HFpEF, independent of blood pressure control.
- 25 September 2025
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 89 (10) , 1719-1721
Open AccessSex-Specific Association Between Calcium-Channel Blocker Use and B-Type Natriuretic Peptide Levels in Elderly Hypertensive Patients With Heart Failure With Preserved Ejection Fraction
Background: The effects of calcium-channel blockers (CCBs) in heart failure with preserved ejection fraction (HFpEF), particularly by sex, remain unclear.Methods and Results: We retrospectively analyzed 412 elderly hypertensive patients with HFpEF (308 women, 104 men). Female CCB users had significantly lower B-type natriuretic peptide (BNP) levels. Multivariable regression showed that CCB use was independently associated with lower BNP, higher EF, and lower tricuspid regurgitation pressure gradient in women, but not in men.Conclusions: CCB use, particularly amlodipine, may be associated with sex-specific hemodynamic benefits in hypertensive elderly women with HFpEF, independent of blood pressure control.
- 1 August 2022
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 323 (2) , H276-H284
β-Blockers are associated with increased B-type natriuretic peptide levels differently in men and women in heart failure with preserved ejection fraction
β-Blocker (BB) use is a mainstay for the treatment of heart failure (HF) with reduced ejection fraction (HFrEF), whereas its efficacy for heart failure with preserved ejection fraction (HFpEF) remains controversial. Women outnumber men in HFpEF, whereas men outnumber women in HFrEF. Plasma B-type natriuretic peptide (BNP) is established as a biomarker for HF. We examined whether BB use is associated with plasma BNP levels differently in men and women with HFpEF. The study subjects comprised 721 patients with HFpEF [left ventricular ejection fraction (LVEF) ≥ 50%] (184 men, mean age 78.2 ± 9.2 yr and 537 women, mean age 83.1 ± 8.8 yr), 179 on BB (66 men and 113 women) and 542 no BB (118 men and 424 women), 583 in sinus rhythm (SR) and 138 in atrial fibrillation (AF). A multivariable logistic regression test was used. Plasma BNP levels were higher (P = 0.0005), systolic blood pressure and LVEF lower (P = 0.0003, and P = 0.0059, respectively) on BBs than on no BBs in women, whereas in men, plasma BNP levels, systolic blood pressure, and LVEF were not altered significantly (P = 0.0849, P = 0.9129, and P = 0.4718, respectively) on BBs compared with no BBs in patients with SR. Multivariable logistic regression analysis revealed that BB use and women were a positive and a negative predictor for high BNP levels (P = 0.003 and P = 0.032, respectively) in SR but not in AF. BB use was associated with high-plasma BNP levels and lower LVEF in women but not in men with HFpEF and SR, suggesting that the pathogenesis and treatment of HFpEF may differ in men and women in SR. NEW & NOTEWORTHY Pathogenesis and treatment for heart failure with preserved ejection fraction (HFpEF) may differ in men and women in sinus rhythm (SR).
- 1 August 2022
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 323 (2) , H276-H284
β-Blockers are associated with increased B-type natriuretic peptide levels differently in men and women in heart failure with preserved ejection fraction
β-Blocker (BB) use is a mainstay for the treatment of heart failure (HF) with reduced ejection fraction (HFrEF), whereas its efficacy for heart failure with preserved ejection fraction (HFpEF) remains controversial. Women outnumber men in HFpEF, whereas men outnumber women in HFrEF. Plasma B-type natriuretic peptide (BNP) is established as a biomarker for HF. We examined whether BB use is associated with plasma BNP levels differently in men and women with HFpEF. The study subjects comprised 721 patients with HFpEF [left ventricular ejection fraction (LVEF) ≥ 50%] (184 men, mean age 78.2 ± 9.2 yr and 537 women, mean age 83.1 ± 8.8 yr), 179 on BB (66 men and 113 women) and 542 no BB (118 men and 424 women), 583 in sinus rhythm (SR) and 138 in atrial fibrillation (AF). A multivariable logistic regression test was used. Plasma BNP levels were higher (P = 0.0005), systolic blood pressure and LVEF lower (P = 0.0003, and P = 0.0059, respectively) on BBs than on no BBs in women, whereas in men, plasma BNP levels, systolic blood pressure, and LVEF were not altered significantly (P = 0.0849, P = 0.9129, and P = 0.4718, respectively) on BBs compared with no BBs in patients with SR. Multivariable logistic regression analysis revealed that BB use and women were a positive and a negative predictor for high BNP levels (P = 0.003 and P = 0.032, respectively) in SR but not in AF. BB use was associated with high-plasma BNP levels and lower LVEF in women but not in men with HFpEF and SR, suggesting that the pathogenesis and treatment of HFpEF may differ in men and women in SR. NEW & NOTEWORTHY Pathogenesis and treatment for heart failure with preserved ejection fraction (HFpEF) may differ in men and women in sinus rhythm (SR).
- 6 June 2022
- Published by Elsevier in International Journal of Cardiology
- Vol. 364, 18-19
Coronary artery spasm: not rare but not fully understood yet
- 6 June 2022
- Published by Elsevier in International Journal of Cardiology
- Vol. 364, 18-19
Coronary artery spasm: not rare but not fully understood yet
- 31 July 2019
- Published by Springer Nature
- Vol. 1193, 121-134
Association of East Asian Variant Aldehyde Dehydrogenase 2 Genotype (ALDH2*2*) with Coronary Spasm and Acute Myocardial Infarction
Coronary spasm plays an important role in the pathogenesis of ischemic heart disease, including angina pectoris, acute myocardial infarction (AMI), silent myocardial ischemia, and sudden death. The prevalence of coronary spasm is higher among East Asians probably due to genetic as well as environmental factors. ALDH2 eliminates toxic aldehydes including 4-hydroxy-2-nonenal (4-HNE) derived from lipid peroxidation and acrolein in tobacco smoking as well as ethanol-derived acetaldehyde and thereby protects tissues and cells from oxidative damage. Deficient variant ALDH2*2 genotype is prevalent among East Asians and is a significant risk factor for both coronary spasm and AMI through accumulation of toxic aldehydes, thereby contributing to oxidative stress, endothelial damage, vasoconstriction, and thrombosis. Toxic aldehydes are thus identified as risk factors to be targeted for the treatment of coronary spasm and AMI.
- 31 July 2019
- Published by Springer Nature
- Vol. 1193, 121-134
Association of East Asian Variant Aldehyde Dehydrogenase 2 Genotype (ALDH2*2*) with Coronary Spasm and Acute Myocardial Infarction
Coronary spasm plays an important role in the pathogenesis of ischemic heart disease, including angina pectoris, acute myocardial infarction (AMI), silent myocardial ischemia, and sudden death. The prevalence of coronary spasm is higher among East Asians probably due to genetic as well as environmental factors. ALDH2 eliminates toxic aldehydes including 4-hydroxy-2-nonenal (4-HNE) derived from lipid peroxidation and acrolein in tobacco smoking as well as ethanol-derived acetaldehyde and thereby protects tissues and cells from oxidative damage. Deficient variant ALDH2*2 genotype is prevalent among East Asians and is a significant risk factor for both coronary spasm and AMI through accumulation of toxic aldehydes, thereby contributing to oxidative stress, endothelial damage, vasoconstriction, and thrombosis. Toxic aldehydes are thus identified as risk factors to be targeted for the treatment of coronary spasm and AMI.
- Open Access
- 8 February 2019
- Published by Japan Academy in Proceedings of the Japan Academy, Series B
- Vol. 95 (2) , 53-66
Coronary artery spasm — Clinical features, pathogenesis and treatment —
Coronary artery spasm (CAS) plays an important role in the pathogenesis of ischemic heart disease, including angina pectoris, myocardial infarction, and sudden death, occurring most often from midnight to early morning. CAS is prevalent among East Asians and is associated with an aldehyde dehydrogenase 2 (ALDH2)-deficient genotype (ALDH2*2) and alcohol flushing, which is prevalent among East Asians but is virtually non-existent in other populations. ALDH2 eliminates not only acetaldehyde but also other toxic aldehydes from lipid peroxidation and tobacco smoking, thereby protecting tissues and cells from oxidative damage. Risk factors for CAS include smoking and genetic polymorphisms including those of ALDH2*2, endothelial NO synthase, paraoxonase I, and interleukin-6. Accordingly, oxidative stress, endothelial dysfunction, and low-grade chronic inflammation play an important role in the pathogenesis of CAS, leading to increased coronary smooth muscle Ca2+ sensitivity through RhoA/ROCK activation and resultant hypercontraction. Ca-channel blockers blocking the intracellular entry of Ca2+ are specifically effective for treatment for CAS.
- 8 February 2019
- Published by Japan Academy in Proceedings of the Japan Academy, Series B
- Vol. 95 (2) , 53-66
Open AccessCoronary artery spasm — Clinical features, pathogenesis and treatment —
Coronary artery spasm (CAS) plays an important role in the pathogenesis of ischemic heart disease, including angina pectoris, myocardial infarction, and sudden death, occurring most often from midnight to early morning. CAS is prevalent among East Asians and is associated with an aldehyde dehydrogenase 2 (ALDH2)-deficient genotype (ALDH2*2) and alcohol flushing, which is prevalent among East Asians but is virtually non-existent in other populations. ALDH2 eliminates not only acetaldehyde but also other toxic aldehydes from lipid peroxidation and tobacco smoking, thereby protecting tissues and cells from oxidative damage. Risk factors for CAS include smoking and genetic polymorphisms including those of ALDH2*2, endothelial NO synthase, paraoxonase I, and interleukin-6. Accordingly, oxidative stress, endothelial dysfunction, and low-grade chronic inflammation play an important role in the pathogenesis of CAS, leading to increased coronary smooth muscle Ca2+ sensitivity through RhoA/ROCK activation and resultant hypercontraction. Ca-channel blockers blocking the intracellular entry of Ca2+ are specifically effective for treatment for CAS.
- 1 October 2018
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 356 (4) , 335-343
Sex Differences in Heart Failure With Preserved Ejection Fraction Reflected by B-type Natriuretic Peptide Level
- 1 October 2018
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 356 (4) , 335-343
Sex Differences in Heart Failure With Preserved Ejection Fraction Reflected by B-type Natriuretic Peptide Level
- 1 October 2017
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 23 (10) , S58
Plasma Levels of BNP Are Lower in Women Than Men among Patients with HFpEF
- 1 October 2017
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 23 (10) , S58
Plasma Levels of BNP Are Lower in Women Than Men among Patients with HFpEF
- 23 August 2016
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 352 (5) , 534-539
Brain Natriuretic Peptide Counteracting the Renin-angiotensin-aldosterone System in Accelerated Malignant Hypertension
- 23 August 2016
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 352 (5) , 534-539
Brain Natriuretic Peptide Counteracting the Renin-angiotensin-aldosterone System in Accelerated Malignant Hypertension
- 20 June 2016
- p. 109-13
[Coronary spasm and its underlying mechanisms].
- Open Access
- 6 May 2016
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 5 (5)
Variant Aldehyde Dehydrogenase 2 ( ALDH2*2 ) Is a Risk Factor for Coronary Spasm and ST‐Segment Elevation Myocardial Infarction
Background: Mitochondrial aldehyde dehydrogenase 2 ( ALDH 2) plays a key role in removing toxic aldehydes. Deficient variant ALDH 2*2 genotype is prevalent in up to 40% of the East Asians and reported to be associated with acute myocardial infarction ( AMI ). To elucidate the mechanisms underlying the association of ALDH 2*2 with AMI , we compared the clinical features of AMI patients with ALDH 2*2 to those with wild‐type ALDH 2*1/*1 . Methods and Results: The study subjects consisted of 202 Japanese patients with acute ST‐ segment elevation myocardial infarction ( STEMI ) (156 men and 46 women; mean age, 67.3±12.0) who underwent primary percutaneous coronary intervention ( PCI ). In 85 patients, provocation test for coronary spasm was also done 6 month post‐ PCI . ALDH 2 genotyping was performed by direct application of the TaqMan polymerase chain system. Of the 202 patients, 103 (51.0%) were carriers of ALDH 2*2 and 99 (49.0%) those of ALDH 2*1/*1 . There were no differences in clinical features between ALDH 2*2 and ALDH 2*1/*1 carrier groups except higher frequencies of coronary spasm and alcohol flush syndrome ( AFS ) (88.6% vs 56.1%; P =0.001 and 94.3% vs 17.6%; P P P =0.002) in the ALDH 2*2 than the ALDH 2*1/*1 carrier group. Conclusions: ALDH 2*2 is prevalent (51.0%) among Japanese STEMI patients, and those with ALDH 2*2 had higher frequencies of coronary spasm and AFS and more‐severe myocardial injury compared to those with ALDH 2*1/*1 .
- 6 May 2016
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 5 (5)
Open AccessVariant Aldehyde Dehydrogenase 2 ( ALDH2*2 ) Is a Risk Factor for Coronary Spasm and ST‐Segment Elevation Myocardial Infarction
Background: Mitochondrial aldehyde dehydrogenase 2 ( ALDH 2) plays a key role in removing toxic aldehydes. Deficient variant ALDH 2*2 genotype is prevalent in up to 40% of the East Asians and reported to be associated with acute myocardial infarction ( AMI ). To elucidate the mechanisms underlying the association of ALDH 2*2 with AMI , we compared the clinical features of AMI patients with ALDH 2*2 to those with wild‐type ALDH 2*1/*1 . Methods and Results: The study subjects consisted of 202 Japanese patients with acute ST‐ segment elevation myocardial infarction ( STEMI ) (156 men and 46 women; mean age, 67.3±12.0) who underwent primary percutaneous coronary intervention ( PCI ). In 85 patients, provocation test for coronary spasm was also done 6 month post‐ PCI . ALDH 2 genotyping was performed by direct application of the TaqMan polymerase chain system. Of the 202 patients, 103 (51.0%) were carriers of ALDH 2*2 and 99 (49.0%) those of ALDH 2*1/*1 . There were no differences in clinical features between ALDH 2*2 and ALDH 2*1/*1 carrier groups except higher frequencies of coronary spasm and alcohol flush syndrome ( AFS ) (88.6% vs 56.1%; P =0.001 and 94.3% vs 17.6%; P P P =0.002) in the ALDH 2*2 than the ALDH 2*1/*1 carrier group. Conclusions: ALDH 2*2 is prevalent (51.0%) among Japanese STEMI patients, and those with ALDH 2*2 had higher frequencies of coronary spasm and AFS and more‐severe myocardial injury compared to those with ALDH 2*1/*1 .